1. Home
  2. PAC vs BMRN Comparison

PAC vs BMRN Comparison

Compare PAC & BMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Grupo Aeroportuario Del Pacifico

PAC

Grupo Aeroportuario Del Pacifico

N/A

Current Price

$229.03

Market Cap

13.9B

ML Signal

N/A

Logo BioMarin Pharmaceutical Inc.

BMRN

BioMarin Pharmaceutical Inc.

N/A

Current Price

$62.05

Market Cap

12.3B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
PAC
BMRN
Founded
1998
1996
Country
Mexico
United States
Employees
N/A
N/A
Industry
Aerospace
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
13.9B
12.3B
IPO Year
2006
1999

Fundamental Metrics

Financial Performance
Metric
PAC
BMRN
Price
$229.03
$62.05
Analyst Decision
Buy
Buy
Analyst Count
7
28
Target Price
★ $246.20
$90.30
AVG Volume (30 Days)
96.7K
★ 2.0M
Earning Date
10-19-2026
11-02-2026
Dividend Yield
★ 4.38%
N/A
EPS Growth
★ N/A
N/A
EPS
N/A
★ 0.14
Revenue
N/A
★ $1,313,646,000.00
Revenue This Year
$43.10
$20.01
Revenue Next Year
$9.94
$14.75
P/E Ratio
★ $27.29
$426.71
Revenue Growth
N/A
★ 17.62
52 Week Low
$192.65
$49.26
52 Week High
$300.41
$70.98

Technical Indicators

Market Signals
Indicator
PAC
BMRN
Relative Strength Index (RSI) 47.81 65.45
Support Level $222.37 $58.03
Resistance Level $254.69 $66.95
Average True Range (ATR) 6.75 2.13
MACD -2.27 0.68
Stochastic Oscillator 7.78 83.75

Price Performance

Historical Comparison
PAC
BMRN

About PAC Grupo Aeroportuario Del Pacifico

Grupo Aeroportuario del Pacifico SAB de CV is engaged in the operation, maintenance, and development of 12 international airports in Mexico and two international airports in Jamaica. The company's segment includes Guadalajara, Tijuana, Puerto Vallarta, San Jose del Cabo, Montego Bay, Hermosillo, and Guanajuato airports. It generates the maximum revenue from the Guadalajara segment.

About BMRN BioMarin Pharmaceutical Inc.

BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.

Share on Social Networks: